These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 23957948

  • 1. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [Abstract] [Full Text] [Related]

  • 4. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
    Dreicer R.
    Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
    [Abstract] [Full Text] [Related]

  • 5. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
    Saad F, Miller K.
    Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
    [Abstract] [Full Text] [Related]

  • 6. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
    Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M.
    Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
    [Abstract] [Full Text] [Related]

  • 7. Progress in the treatment of advanced prostate cancer.
    Sternberg CN, Petrylak DP, Madan RA, Parker C.
    Am Soc Clin Oncol Educ Book; 2014 Apr; ():117-31. PubMed ID: 24857068
    [Abstract] [Full Text] [Related]

  • 8. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 9. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 10. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR, Hussain MH.
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
    Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.
    Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
    [Abstract] [Full Text] [Related]

  • 13. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
    Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J.
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
    [Abstract] [Full Text] [Related]

  • 14. Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.
    dela Rama F, Pratz C.
    Clin J Oncol Nurs; 2015 Dec; 19(6):723-32. PubMed ID: 26583636
    [Abstract] [Full Text] [Related]

  • 15. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [Abstract] [Full Text] [Related]

  • 16. Current therapeutic options in metastatic castration-resistant prostate cancer.
    Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R.
    Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
    [Abstract] [Full Text] [Related]

  • 17. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
    [Abstract] [Full Text] [Related]

  • 18. Emerging agents for the therapy of advanced prostate cancer.
    Hathaway AR, Baker MK, Sonpavde G.
    Future Oncol; 2015 Dec; 11(20):2775-87. PubMed ID: 26367474
    [Abstract] [Full Text] [Related]

  • 19. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS, Crawford ED.
    Urol Oncol; 2011 Dec; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [Abstract] [Full Text] [Related]

  • 20. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
    Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB.
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):111-21. PubMed ID: 26832363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.